2021•Annals of OncologyOpen access

117O Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials

Valentina Guarneri, Gaia Griguolo, Federica Miglietta, PierFranco Conte, Maria Vittoria Dieci, Fabio Girardi

Open full text 4 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Lapatinib, Trastuzumab, Oncology, Breast cancer, Internal medicine, Meta-analysis, Neoadjuvant therapy

Back to paper search Browse research topics Original source

117O Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials — Research Paper | ScholarLens